Multimodality treatment in advanced prostate cancer

European Urology, Supplements

Volumn 3, Issue 3, 2004, Pages 51-57

  Heidenreich, Axel ^a  

^a UNIVERSITY OF COLOGNE   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

ANDROGEN RECEPTOR; ANTIANDROGEN; BICALUTAMIDE; BISPHOSPHONIC ACID DERIVATIVE; CISPLATIN; CLODRONIC ACID; CYTOTOXIC AGENT; DOCETAXEL; DOXORUBICIN; ESTRAMUSTINE PHOSPHATE; ETIDRONIC ACID; ETOPOSIDE; GOSERELIN; IBANDRONIC ACID; MITOXANTRONE; PACLITAXEL; PAMIDRONIC ACID; RISEDRONIC ACID; TAXANE DERIVATIVE; VINBLASTINE; WARFARIN; ZOLEDRONIC ACID;

ADJUVANT CHEMOTHERAPY; ADVANCED CANCER; BLOOD TOXICITY; BONE METASTASIS; BREAST CANCER; CANCER ADJUVANT THERAPY; CANCER CELL; CANCER GROWTH; CANCER HORMONE THERAPY; CANCER INVASION; CLINICAL TRIAL; CONFERENCE PAPER; DEEP VEIN THROMBOSIS; DRUG EFFICACY; GENE MUTATION; HORMONAL REGULATION; HUMAN; MOLECULAR BIOLOGY; MULTIMODALITY CANCER THERAPY; NEUTROPENIA; NONHUMAN; PRIORITY JOURNAL; PROSTATE CANCER; RECEPTOR GENE; SIDE EFFECT;

EID: 1542328905     PISSN: 15699056     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.eursup.2004.02.009     Document Type: Conference Paper

References (46)

1. Moul J.W. Prostate specific antigen only progression of prostate cancer. J. Urol. 163:2000;1632-1642.
2. Hull G.W., Rabbani F., Abbas F., Wheler T.M., Kattan M.W., Scardino P.T. Cancer control with radical prostatectomy alone in 1000 consecutive patients. J. Urol. 167:2002;528-534.
3. Isaacs J.T., Coffey D.S. Adaption versus selection as the mechanism responsible for the relapse of prostatic cancer to androgen ablation therapy as studied in the Dunning R- 3327-H adenocarcinoma. Cancer Res. 41:1981;5070.
4. Henry J.M., Isaacs J.T. Relationship between tumor size and the curability of metastatic prostate cancer by surgery alone or in combination with adjuvant chemotherapy. J. Urol. 139:1988;1119-1124.
5. Lau W.K., Bergstralh E.J., Blute M.L., Slezak J.M., Zincke H. Radical prostatectomy for pathological Gleason 8 or greater prostate cancer: influence of concomitant pathological variables. J. Urol. 167:2002;117-122.
6. Akduman B., Crawford E.D. The management of high risk prostate cancer. J. Urol. 169:2003;1993-1998.
7. Bruchovsky N., Rennie P.S., Coldman A.J., Goldenberg S.L., To M., Lawson D. Effects of androgen withdrawal on the stem cell composition of the Shionogi carcinoma. Cancer Res. 50:1990;2275.
8. Tso C.L., McBride W.H., Sun J., Patel B., Tsui K.H., Paik S.H, et al. Androgen deprivation induces selective outgrowth of aggressive hormone-refractory prostate cancer clones expressing distinct cellular and molecular properties not present in parenteral androgen-dependent cancer cells. Cancer J. 6:2000;220-233.
9. Grossman M.E., Huang H., Tindall D.J. Androgen receptor signaling in androgen- refractory prostate cancer. J. Natl. Cancer Inst. 93:2001;1687-1897.
10. Denmeade S.R., Lin X.S., Isaacs J.T. Role of programmed cell death during the progression and therapy of prostate cancer. Prostate. 28:1996;251.
11. Berchem B.J., Bosseler M., Sugars L.Y, et al. Androgens induce resistance to bcl-2 mediated apoptosis in LNCaP-prostate cancer cells. Cancer Res. 55:1995;735-738.
12. Haldar S., Jena N., Croce C.M. Inactivation of bcl-2 by phosphorylation. Proc. Natl. Acad. Sci. USA. 92:1995;4507-4511.
13. Halder S., Chintapalli J., Croce J.M. Taxol induces bcl-2 phosphorylation and death of prostate cancer cells. Cancer Res. 56:1996;1253-1255.
14. Guise T.A., Mundy G.R. Cancer and bone. Endocr. Rev. 19:1998;18-54.
15. Diaz J.F., Andreu J.M. Assembly of purified GTP-tubulin into microtubules induced by taxol and taxotere: reversibility, ligand stoichiometry and competition. Biochem. 32:1993;2747-2755.
16. Manfredi J.J., Parness J., Horwitz S.B. Taxol binds cellular microtubules. J. Cell Biol. 94:1982;688-696.
17. Heidenreich A., Schrader A.J. The treatment of hormone refractory prostate cancer. EAU Update Series. 1:2003;40-50.
18. El-Rayes B.F., Hussain M., Smith D., Fontana J., Vaishampyan U., Sakr W, et al. Neo- adjuvant docetaxel and estramustine in patients with high risk/locally advanced prostate cancer. Proc. ASCO. 21:2002;773.
19. Ko Y.J., Dewolf A., Ilumi A., Sesterhenn I.A., Upton M., Bubley G.J. Neoadjuvant chemo- hormonal therapy in followed by radical prostatectomy for high risk prostate cancer. Proc. ASCO. 21:2002;2465.
20. Oh W.K., George D.J., Prisby J, et al. Neoadjuvant docetaxel chemotherapy followed by radical prostatectomy in patients with high risk localized prostate cancer: preliminary results. Proc. ASCO. 20:2001;187a.
21. Hussain A., Dawson N., Amin P., Naslund M., Engstrom C., Chen T. Docetaxel followed by hormone therapy after failure of definitive treatments for clinically localized/locally advanced prostate cancer: preliminary results. Sem. Oncol. 28(Suppl 15):2001;22-31.
22. Taplin M.E., Bubley G.J., Rajeshkumar B., Shuster T., Ko Y.J., Morganstern D.E. Docetaxel, estramustine and short-term androgen withdrawal for patients with biochemical failure after definitive local therapy for prostate cancer. Sem. Oncol. 28(Suppl 15):2001;32-39.
23. Batson O.V. The function of the vertebral veins and their role in the spread of metastasis. Ann. Surg. 112:1940;138.
24. Paterson A.H.G. The potential role of bisphosphonates as adjuvant therapy in the prevention of bone metastases. Cancer (Suppl). 88:2000;3038-3046.
25. Heidenreich A. Bisphosphonates in the management of metastatic prostate cancer. Oncology. 65(Suppl.):2003;5-11.
26. Diel I.J., Solomeyer E.P., Costa S., Gollan C., Goerner R., Wallwiener D, et al. Reduction of new metastases in breast cancer with adjuvant clodronate treatment. N. Engl. J. Med. 339:1998;357-363.
27. Saarto T., Blomqvist C., Birkkunen P, et al. Adjuvant clodronate treatment does not reduce the frequency of skeletal metastases in node positive breast cancer patients: 5- year results of a randomized controlled trial. J. Clin. Oncol. 19:2001;10-17.
28. Powells T., Paterson S., Kanis J.A., McCloskey E., Ashley S, et al. Randomized, placebo- controlled trial of clodronate in patients with primary operable breast cancer. J. Clin. Oncol. 20:2002;3219-3224.
29. Boissier S., Ferreras M., Peyruchaud O., Magnetto S., Ebetino F.H., Colombel M, et al. Bisphosphonates inhibit breast and prostate carcinoma cell invasion, an early event in the formation of bone metastases. Cancer Res. 60:2000;2949-2954.
30. Boissier S., Magnett S., Frapard L., Cuzin B., Ebetino F.H., Delmas P.D, et al. Bisphosphonates inhibit prostate and breast carcinoma cell adhesion to unmineralized and mineralized bone extracellular matrices. Cancer Res. 57:1997;3890-3894.
31. Santini D., Vincenzi B., Avvisati G., Dicuonzo G., Battistoni F., Gavasci M, et al. Pamidronate induces modifications of circulating angiogenetic factors in cancer patients. Clin. Cancer Res. 8:2002;1080-1084.
32. Stearns M.E., Wang M. Alendronate blocks metalloproteinase secretion and bone collagen I release by PC-3 ML cells in SCID mice. Clin. Exp. Metastasis. 16:1998;693-702.
33. Stearns M.E. Alendronate blocks TGF-beta 1 stimulated collagen 1 degradation by human prostate PC-3 ML cells. Clin. Exp. Metastasis. 16:1998;332-339.
34. Lee M.V., Fong E.M., Singer F.R., Guenette R.S. Bisphosphonate treatment inhibits the growth of prostate cancer cells. Cancer Res. 61:2001;2602-2608.
35. Lee Y.P., Schwarz E.M., Davies M., Jo M., Gates J., Zhang X, et al. Use of zoledronate to treat osteoblastic versus osteolytic lesions in a severe-combined- immunodeficient mouse model. Cancer Res. 62:2002;5564-5570.
36. Cheng S.Y., Geldorf A.A., Newling D.W.W., Rao B.R. Progression delay of prostate tumor skeletal metastasis effects by bisphosphonates. J. Urol. 148:1992;1270-1273.
37. Magnetto S., Boissier S., Delmas P.D., Clezardin P. Additive antitumor activities of taxoids in combination with the bisphosphonate ibandronate against invasion and adhesion of human breast carcinoma cells to bone. Int. J. Cancer. 83:1999;263-269.
38. Stearns M.E., Wang M. Effects of alendronate and taxol on PC-3 cell bone metastases in SCID mice. Invasion Metastasis. 16:1996;116-131.
39. Oh W.K., Kanthoff P.W. Treatment of locally advanced prostate cancer: is chemotherapy the next step? J. Clin. Oncol. 17:1999;3664-3675.
40. Schmidt J.D., Gibbons R.P., Murphy G.P, et al. Adjuvant estramustine phosphate treatment for localized prostate cancer. PPO Updates. 11:1997;1.
41. Pummer K., Lehnert M., Stettner H., Hubmer G. Randomized comparison of total androgen blockade alone versus combined with weekly epirubicin in advanced prostate cancer. Eur. Urol. 32(Suppl.):1997;81.
42. Wang J., Halford S., Rigg A., Roylance R., Lynch M., Waxman J. Adjuvant mitoxantrone chemotherapy in advanced prostate cancer. Brit. J. Urol. Int. 86:2000;675-680.
43. Bagley C.M., Lane R.F., Blasko J.C., Grimm P.D., Ragde H., Cobb O.E, et al. Adjuvant chemohormonal therapy of high risk prostate carcinoma. Cancer. 94:2002;2728-2732.
44. Vaishampayan U., Hussain M. Adjuvant chemo/hormonal therapy trials for locally advanced prostate cancer. Curr. Oncol. Rep. 2:2000;402-408.
45. Partin A.W., Piantadosi S., Sanda M.G., Epstein J.I., Marshall F.E., Mohler J.L, et al. Selection of men at high risk for disease recurrence for experimental adjuvant therapy following radical prostatectomy. Urology. 45:1995;831-838.
46. Graefen M., Karakiewicz P.I., Cagiannos I., Klein E., Kupelian P.A., Quinn D.I, et al. Validation study of the accuracy of a postoperative nomogram for recurrence after radical prostatectomy for localized prostate cancer. J. Clin. Oncol. 20:2002;951-956.